	US 12,357,683 B2
	Vaccines against Nipah virus, and methods of using same
Kar Muthumani, Cherry Hill, NJ (US); and David Weiner, Merion, PA (US)
Assigned to The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
Appl. No. 17/269,409
Filed by THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US)
PCT Filed Aug. 21, 2019, PCT No. PCT/US2019/047410 § 371(c)(1), (2) Date Feb. 18, 2021, PCT Pub. No. WO2020/041410, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/720,393, filed on Aug. 21, 2018.
Prior Publication US 2021/0252134 A1, Aug. 19, 2021
Int. Cl. A61K 39/155 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01)

CPC A61K 39/155 (2013.01) [A61P 31/14 (2018.01); A61P 37/04 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); C12N 2760/18222 (2013.01); C12N 2760/18234 (2013.01); C12N 2760/18271 (2013.01)]

13 Claims

1. A nucleic acid molecule encoding at least one consensus Nipah virus (NiV) antigen, wherein the nucleic acid molecule comprises a sequence selected from the group consisting of

a) a nucleotide sequence having at least 98% identity over an entire length of the nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:5,

b) an immunogenic fragment comprising at least 98% identity over at least 60% of the nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:5, and

c) the nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:5.